April 15, 2025

Strategic Showdown in Japan: AstraZeneca and Johnson & Johnson Target Accelerated Growth Through Innovation and New Modalities (2025-2030)

This is an unadulterated report (apart from some formatting), created by Gemini Advanced Deep Research 2.5. I wrote the prompt after seeing a tiny bit of information on Astra Zeneca's ambitious goals for Japan on my phone. And I was curious as to how this would compare to J&J's also rather ambitious Japan drive. Personally: I'm impressed with this report! It took Gemini less time than it took me to practice kendo… It makes for excellent reading and, I particularly enjoy that it gives recommendations to all stakeholders, including the PMDA 🙂

1. Executive Summary

The Japanese pharmaceutical market, a globally significant arena, is poised for intensified competition as two major multinational corporations, AstraZeneca (AZ) and Johnson & Johnson (J&J) via its Janssen Pharmaceutical Companies, pursue highly ambitious growth strategies centered on innovation and rapid pipeline advancement. Both companies have set aggressive targets for regulatory approvals in Japan through the end of the decade – AZ aiming for over 40 approvals between 2025 and 2030, and J&J targeting approximately 50 by 2029. These goals underscore Japan's enduring strategic importance despite persistent pricing pressures.

Both AZ and J&J are leveraging their substantial global R&D engines and deep pipelines, relying heavily on bringing next-generation therapies, particularly "new modalities" like antibody-drug conjugates (ADCs), bispecific antibodies, cell therapies, and gene therapies, to the Japanese market. Oncology and Immunology represent key battlegrounds where their therapeutic focuses significantly overlap. However, differentiation exists, with J&J demonstrating a stronger late-stage emphasis on Neuroscience, while AZ maintains prominent pipelines in Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Diseases via its Alexion unit.

While both companies utilize partnerships extensively, their strategic approaches show nuances. AZ highlights a unique focus on leveraging Real-World Data (RWD) through a dedicated platform, positioning itself as an ecosystem partner within Japan. J&J appears to emphasize the sheer scale and breadth of its global pipeline deployment, coupled with aggressive acquisition of specific technologies and assets, including notable investments in cell and gene therapy capabilities.

The parallel push by these two giants promises to accelerate patient access to cutting-edge treatments in Japan, addressing unmet needs driven by the nation's aging demographics. However, it will also significantly heighten competitive pressure, potentially impacting market dynamics, pricing, and the need for healthcare system adaptation to accommodate complex new therapies. Success will hinge not only on clinical innovation but also on effective market access, speed, and potentially novel value demonstration strategies.

2. The Japanese Pharmaceutical Market: A Strategic Arena

Japan stands as one of the world's largest and most strategically vital pharmaceutical markets, consistently ranking among the top three globally.[1] While estimates vary, recent reports place its market size at approximately USD 82.3 billion in 2024, with projections reaching around USD 101.9 billion by 2033 (CAGR ~2.6%) [3], or USD 95.9 billion in 2025 growing to USD 100.4 billion by 2030 (CAGR ~0.9%).[4] This substantial market value, situated within a global pharmaceutical landscape that expanded dramatically from USD 499 billion in 2003 to USD 1.47 trillion in 2022 [5], makes Japan a critical territory for multinational pharmaceutical companies seeking sustained growth.

2.1 Market Size and Growth Dynamics

The primary driver of growth within the Japanese pharmaceutical market is its rapidly aging population.[3] This demographic shift leads to an increased prevalence of chronic and age-related diseases, including cardiovascular conditions, diabetes, cancers, and neurodegenerative disorders like Alzheimer's and Parkinson's disease.[3] For instance, cancer incidence remains high, with significant numbers for colorectal, lung, stomach, and pancreatic cancers reported annually.[4] Neurological conditions such as Parkinson's disease, epilepsy, stroke, and dementia also affect a substantial portion of the population.[4] This demographic reality fuels a growing demand for medications and advanced medical care, creating a steady expansion

of healthcare needs.[6] Furthermore, the Japanese pharmaceutical industry is a significant contributor to the national economy, ranking highly in technology trade balance and tax contributions.[5]

2.2 Key Challenges and Opportunities

Despite its attractiveness, the Japanese market presents distinct challenges. Persistent **drug pricing pressure** from government policies, including annual price revisions and potentially tighter controls on new medicine pricing, impacts profitability and requires careful strategic navigation.[4] The April 2024 drug price system reform was noted by J&J's Japan President as a factor requiring strategic adaptation to maintain Japan's market appeal for global development pipelines.[9]

Historically, Japan has also faced issues of **"drug lag"** (delays in approving drugs available elsewhere) and **"drug loss"** (drugs approved internationally but never launched in Japan).[9] While this creates unmet medical needs, it simultaneously presents an opportunity for companies demonstrating a strong commitment to rapidly bringing global innovations to Japanese patients.[9]

The market environment necessitates a strong **innovation imperative**. Continuous investment in R&D, particularly focusing on novel therapeutic modalities such as cell and gene therapies, ADCs, bispecific antibodies, and RNA therapies, is crucial for competitiveness.[3] The Japan Pharmaceutical Manufacturers Association (JPMA) explicitly highlights the promotion of domestic development and adoption of these new modalities as a key industry goal.[11] The integration of artificial intelligence (AI) and machine learning (ML) into drug discovery, development, and manufacturing is also recognized as a significant supporting trend.[3]

Partnerships are another vital element for success. Collaborations spanning industry-academia-government links, pharma-pharma co-development or co-promotion agreements, and pharma-biotech licensing deals are essential strategies for accessing cutting-edge science, sharing development costs and risks, and effectively navigating the complex market landscape.[1]

2.3 Strategic Implications

The significant strategic focus placed on Japan by major global players like AstraZeneca and Johnson & Johnson, evidenced by their ambitious multi-year approval targets [9], persists despite the acknowledged pricing challenges. This

indicates a long-term perspective where the substantial unmet medical needs of the aging population [3], combined with the potential for truly innovative therapies (especially new modalities [10]) to achieve favorable market access, outweigh the risks associated with pricing controls. These companies appear to be betting on the high value of breakthrough treatments in areas like oncology and immunology to secure a strong position in this indispensable market.[1]

The explicit framing of J&J's large approval target (~50 by 2029) within the context of Japan's historical drug lag/loss issues [9] suggests a deliberate competitive strategy. By positioning itself as a company capable of accelerating the delivery of globally available, innovative medicines to Japanese patients, J&J aims to differentiate itself, potentially capturing market share and building significant goodwill within the healthcare system.

The convergence of several key trends—Japan's aging demographic profile creating demand for treatments targeting complex diseases [3], government and industry emphasis on fostering pharmaceutical innovation [11], and the global pharmaceutical sector's widespread investment in new therapeutic modalities [8]—creates an exceptionally favorable environment for companies like AZ and J&J. Their strong pipelines, rich in these advanced therapies, are well-aligned with both the market's needs and the strategic direction of the industry, positioning Japan as a prime market for deploying their most advanced assets.

3. AstraZeneca's Vision for Japan: Targeting 40+ Approvals by 2030

AstraZeneca has articulated a clear and ambitious strategy for the Japanese market, centered around a goal of securing **over 40 regulatory approvals between 2025 and 2030**.[15] This target encompasses both entirely new pharmaceutical products and significant expansions of indications for its existing portfolio.[15] This objective is embedded within a broader corporate vision for AstraZeneca Japan: to be the "No.1 pioneer in changing patients' lives through innovation".[15]

3.1 Dissecting the Approval Goal

The 40+ approval target in Japan aligns with, yet distinctively scales, AstraZeneca's global ambitions. Globally, the company aims to achieve $80 billion in total revenue

by 2030 (a significant increase from $45.8 billion in 2023) and launch 20 new medicines worldwide before the end of the decade.[17] The numerically higher target for Japan (40+ *approvals* versus 20 global *new medicines*) strongly suggests that a substantial portion of the Japanese goal will be achieved through Life Cycle Management (LCM) – securing approvals for new uses and indications of already established drugs. This approach maximizes the value derived from their existing successful portfolio within the crucial Japanese market, complementing the introduction of novel therapies.

3.2 Therapeutic Area Priorities

AstraZeneca's strategy in Japan is anchored in its core global therapeutic areas:

- **Oncology:** This remains a cornerstone of AstraZeneca's strength and focus in Japan.[15] The company has a deep pipeline and portfolio, including key assets like *Imfinzi* (durvalumab), with recent or anticipated approvals/studies in endometrial, gastric, GEJ, and lung cancers.[22] Other pillars include *Lynparza* (olaparib) [22], *Tagrisso* (osimertinib) [18], *Calquence* (acalabrutinib) [22], and the highly successful antibody-drug conjugates (ADCs) *Enhertu* (trastuzumab deruxtecan), partnered with Daiichi Sankyo [26], and *Datroway* (datopotamab deruxtecan).[22] The late-stage global pipeline is replete with oncology candidates, many involving new modalities.[19]
- **Biopharmaceuticals (CVRM and R&I):** These areas are significant growth drivers for AstraZeneca Japan, with reported growth of 13% (CVRM) and 18% (R&I) in 2024.[15] Key marketed products include *Fasenra* (benralizumab) for eosinophilic conditions [22], *Tezspire* (tezepelumab) for severe asthma and potentially other indications [18], *Saphnelo* (anifrolumab) for lupus [18], *Lokelma*, *Breztri*, and *Airsupra*.[18] The pipeline features promising candidates like *tozorakimab* (an IL-33 mAb for COPD/LRTI) [19] and combination therapies for chronic kidney disease (CKD) such as *zibotentan/dapagliflozin* and *baxdrostat/dapagliflozin*.[19]
- **Rare Disease:** Leveraged through its Alexion acquisition, this is a core global focus.[18] Key assets include *Ultomiris* (ravulizumab) [18] and *Koselugo* (selumetinib). A notable pipeline asset for Japan is *acoramidis*, an oral TTR stabilizer for ATTR-CM licensed from BridgeBio specifically for the Japanese market.[19] Other late-stage candidates include *ALXN2220* (a TTR depleter) and *gefurulimab* (a bispecific antibody for generalized myasthenia gravis).[19]
- **Vaccines & Immune Therapies:** This area includes *Kavigale* (sipavibart), a

long-acting antibody (LAAB) for the prevention of COVID-19, which has received attention in Japan.[19]

3.3 Harnessing New Modalities

AstraZeneca explicitly states that embracing "new modalities," such as **bispecific antibodies**, is fundamental to achieving its ambitious 40+ approval target in Japan.[15] This aligns perfectly with the company's global strategy, which emphasizes continued investment in transformative technologies and platforms that will shape the future of medicine.[17] Key new modality platforms being pursued globally and reflected in the pipeline include:

- **Antibody-Drug Conjugates (ADCs) and Radioconjugates:** Aiming to replace systemic chemotherapy and radiotherapy with more targeted approaches.[18] Examples: *Enhertu*, *Datroway*, AZD0901.[19]
- **Cell Therapy and T-cell Engagers:** Developing scalable therapies across various therapy areas.[18] Examples: AZD0486 (CD19/CD3 T-cell engager).[19]
- **Gene Therapy and Genomic Medicines:** Exploring oligonucleotides, RNA-based therapies, CRISPR/Cas9, and AAVs.[18] Example: *Wainua* (eplontersen), a ligand-conjugated antisense oligonucleotide (ASO).[18]
- **Next-Generation Immuno-Oncology (IO) Bispecifics:** Targeting multiple pathways simultaneously.[18] Examples: *rilvegostomig* (PD-1/TIGIT), *volrustomig* (PD-1/CTLA-4), *gefurulimab* (rare disease bispecific).[19]
- **Other Biologics:** Including LAABs like *Kavigale*.[19]

This diverse technological toolbox is clearly being deployed to fuel the Japanese pipeline towards the 2030 goal.

3.4 Strategic Levers in Japan

Beyond its pipeline, AstraZeneca employs specific strategic levers within the Japanese market:

- **Real-World Data (RWD) Utilization:** AstraZeneca has made a significant, differentiating investment in building a sophisticated data platform in Japan. This platform leverages anonymized healthcare data (including hospital and insurer receipts, electronic medical records) from over 90 million individuals, enabling timely in-house analysis.[15] Underscoring this commitment, AZ Japan received the first certification as a business operator utilizing anonymized medical information in February 2025.[15] The stated aim extends beyond drug

development; AstraZeneca intends to use RWD to help "transform care," address challenges faced by local medical communities, contribute to extending healthy life expectancy, and generate robust Japan-specific evidence.[15] A tangible example is their partnership with Fukushima Prefecture focused on COPD prevention and management.[15] This prominent RWD strategy represents more than just an R&D tool; it positions AstraZeneca as a potential partner to the broader Japanese healthcare system, including local governments and medical associations. By generating unique, localized evidence and collaborating on healthcare challenges, AZ may gain a competitive edge in demonstrating value, potentially supporting market access and reimbursement negotiations for its innovative therapies.

- **Strategic Partnerships:** AstraZeneca has a strong history of successful collaborations in Japan. Notable examples include the highly fruitful partnership with Daiichi Sankyo yielding *Enhertu* [26], a past co-promotion agreement with Daiichi Sankyo for denosumab [1], and a co-promotion deal with Janssen for abiraterone acetate.[12] The company actively seeks further partnerships in Japan, particularly focusing on opportunities at or near the commercial launch stage within its core therapeutic areas. This interest extends beyond pharmaceuticals to include diagnostics, medical devices, and digital technologies, aiming to build comprehensive, end-to-end patient solutions.[13] This dual approach—developing internally while actively sourcing externally, as seen with the Japan-specific license for *acoramidis* [30]—allows AZ to rapidly build and diversify its pipeline to meet its ambitious targets.
- **Established Local Presence:** AstraZeneca maintains a significant footprint in Japan, encompassing Commercial, R&D (Osaka), and Operations functions.[1] This local infrastructure supports its commercial activities and demonstrates a long-term commitment to the market, fostering a patient-first culture adapted to local needs.[21]

4. Johnson & Johnson's Competitive Stance in Japan

Johnson & Johnson, through its Janssen Pharmaceutical Companies, presents a formidable competitive force in Japan, mirroring AstraZeneca's high level of ambition and strategic focus on innovation.

4.1 Strategic Objectives and Approval Pipeline

Janssen Pharma Japan has publicly declared its goal to secure **approximately 50**

approvals – including new drugs and expanded indications – by the year **2029**.[9] This target underpins an aspiration for **double-digit growth by 2027** within the Japanese market.[9] This ambition is supported by J&J's consistent global track record of high R&D productivity, having targeted numerous new molecular entity (NME) filings and launches globally in preceding five-year cycles (e.g., >10 NMEs 2017-2021, >10 NMEs 2019-2023) alongside substantial numbers of line extensions (>50 by 2021, >40 by 2023).[33]

J&J emphasizes a disciplined R&D investment strategy and portfolio transformation.[35] Its strategy appears heavily reliant on leveraging its global scale and broad, multi-modality pipeline to fuel growth in Japan. The sheer volume and diversity of innovative launches planned across multiple key therapeutic areas suggest an approach aimed at establishing strong positions across a wide front. Key pipeline assets with relevance to the Japanese market, based on global pipeline data and specific mentions, include:

- **Oncology:** *Rybrevant* (amivantamab) for lung cancer (approved Sept 2024 in Japan [9]; multiple Phase 3 trials ongoing [36]), *Tecvayli* (teclistamab) and *Talvey* (talquetamab) bispecifics for multiple myeloma (Tecvayli pending approval [9]; both in Phase 3 [36]), *Carvykti* (cilta-cel) CAR-T therapy for multiple myeloma (approved Sept 2022 in Japan [38]; Phase 3 trials ongoing [36]), *Erleada* (apalutamide) for prostate cancer (Phase 3 [36]), and novel delivery systems like TAR-200/TAR-210 for bladder cancer.[36]
- **Immunology:** *Tremfya* (guselkumab) for inflammatory bowel disease (pending approval [9]; extensive Phase 3/Registration program [36]), *Nipocalimab* (an anti-FcRn antibody acquired via Momenta [39]) for various autoimmune diseases including myasthenia gravis (Phase 3/Registration [36]), and *Icotrokinra* (an oral IL-23 receptor peptide) for Psoriasis (Phase 3 [36]). Also includes established biologics *Stelara* and *Simponi* with pediatric indications in late stage.[36]
- **Neuroscience:** *Spravato* (esketamine) for depression (Phase 3/Registration [34]), *aticaprant* (kappa-opioid receptor antagonist) for depression (Phase 3 [36]), *seltorexant* for depression/insomnia (Phase 3 [36]), and gene therapies for retinal diseases.[36]
- **Other:** *Milvexian* (Factor XIa inhibitor) for thrombosis prevention (Phase 3 [36]).

4.2 Therapeutic Focus

Janssen's strategic priorities for Japan explicitly name **Oncology, Immunology, and Psychiatric/Neurological Diseases** as the core pillars.[9] This aligns well with

J&J's global therapeutic area strongholds, which include Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism, Oncology, and Pulmonary Hypertension, with Retina emerging as a significant focus.[33] The extensive late-stage pipeline confirms deep investments in these areas.[36]

4.3 Embracing Next-Generation Therapies

J&J is aggressively pursuing leadership in next-generation therapeutics, making substantial investments across various advanced modalities:

- **Cell Therapy:** J&J has established a significant presence with the approval of *Carvykti* (cilta-cel) in Japan for multiple myeloma.[38] They are actively expanding this, with Phase 3 trials for earlier lines of therapy [36] and strategic moves to secure future assets. This includes a worldwide collaboration with Cellular Biomedicine Group (CBMG) for novel CD20/CD19-targeting CAR-Ts (C-CAR039, C-CAR066) [42] and the acquisition of Serotiny, a company specializing in CAR design platforms.[44] This multi-pronged approach signals a strong commitment to becoming a leader in cell therapy within Japan.
- **Gene Therapy:** J&J is advancing gene therapies, particularly in ophthalmology. Their pipeline includes a Phase 3 candidate (RPGR Gene Therapy / bota-vec) for X-linked retinitis pigmentosa, developed via collaboration with MeiraGTx [36], and JNJ-1887 for geographic atrophy (Phase 2b).[41]
- **Bispecific Antibodies:** This is a major focus, especially within hematologic oncology. Key assets include *Rybrevant* (EGFR/MET for solid tumors) [36], *Tecvayli* (BCMA/CD3 for myeloma) [36], and *Talvey* (GPRC5D/CD3 for myeloma).[36] J&J utilizes various platforms, including collaborations with Genmab (DuoBody®) [45], Zymeworks (Azymetric™) [46], and Xencor (XmAb® for CD28 bispecifics).[46]
- **Other New Modalities:** J&J's pipeline also features ADCs (e.g., collaborations with Ambrx [36] and Hangzhou DAC [46]), novel oral therapies for immunology like the peptide *Icotrokinra* [36] and the STAT6 inhibitor KP-723 (licensed from Kaken) [47], peptide discovery platforms (via PeptiDream collaboration [49]), RNA therapeutics (mentioned as a focus area [34]), and innovative drug delivery systems (intravesical TAR-200/TAR-210 [36]).

4.4 Market Engagement in Japan

J&J actively engages with the Japanese market through various mechanisms:

- **Licensing and Collaborations:** J&J demonstrates a clear strategy of complementing its internal pipeline by accessing external innovation, including specific Japanese sources. Recent examples include licensing the STAT6 inhibitor program (KP-723) from Kaken Pharmaceutical with a co-promotion option in Japan [47], collaborating with PeptiDream on its peptide discovery platform [49], and partnering with the University of Tokyo on a diagnostic biosensor.[49] Globally relevant deals also impact Japan, such as the acquisition of Momenta Pharmaceuticals bringing *Nipocalimab* [39], and the partnership with Legend Biotech for *Carvykti*.[38] Historically, J&J has partnered with Japanese companies like Nippon Shinyaku (global rights for *Uptravi* [50]), AstraZeneca (co-promotion [12]), and Mitsubishi Tanabe (co-development [51]). This suggests a dual approach: deploying global assets while actively tapping into the local innovation ecosystem.
- **Local Leadership and Presence:** The appointment of Shuhei Sekiguchi as President of Janssen Pharma Japan underscores the importance of local leadership focused on maximizing patient access, organizational development, and cultural integration.[9] The presence of Johnson & Johnson Innovation Asia Pacific, including a dedicated Japan Country Lead, facilitates deal-making and ecosystem engagement.[49]
- **Strategic Rationale:** President Sekiguchi explicitly connects the ambitious ~50 approval target to leveraging J&J's "world-leading development capabilities and execution capabilities in Japan".[9] This highlights the strategy of deploying the might of its global R&D engine (ranking among the top R&D investors worldwide [9]) effectively within the local market context.

5. Comparative Analysis: AstraZeneca vs. Johnson & Johnson in the Japanese Arena

The strategic initiatives of AstraZeneca and Johnson & Johnson set the stage for intense competition within the Japanese pharmaceutical market through 2030. Both companies share a high level of ambition, targeting a significant number of regulatory approvals driven by innovation, particularly in new therapeutic modalities.

5.1 Ambition and Scale

Both AZ and J&J have set remarkably similar, high-volume approval targets for Japan (AZ: 40+ by 2030; J&J: ~50 by 2029).[9] These figures signal not only the

strategic importance they place on Japan but also their confidence in the productivity of their respective pipelines. Achieving these numbers will necessitate a blend of launching novel NMEs derived from their global R&D efforts [17] and maximizing the value of existing blockbuster products through numerous line extensions and indication expansions (LCM).[19] Both companies command substantial global resources to support these endeavors.[9]

5.2 Therapeutic Footprints

Significant competitive overlap is evident, particularly in **Oncology** and **Immunology**. Both companies possess deep and diverse pipelines in these areas, featuring multiple next-generation therapies including ADCs, bispecific antibodies, IO agents, targeted small molecules, and novel biologics.[19] This guarantees head-to-head competition for market share in treating major cancers and autoimmune diseases.

However, areas of potential differentiation exist. J&J has a more pronounced strategic focus and a richer late-stage pipeline in **Neuroscience**, covering depression, Alzheimer's, and other neurological conditions.[9] Conversely, AstraZeneca appears to have a stronger late-stage emphasis on **CVRM** and **Respiratory**, building on established franchises [15], and maintains a dedicated **Rare Disease** unit (Alexion) with a distinct portfolio and pipeline.[18]

5.3 New Modality Race

Both companies are heavily invested in the development and deployment of new therapeutic modalities, recognizing them as critical drivers of future growth.[18] Their strengths, however, appear somewhat differentiated in the near-to-medium term:

- **AstraZeneca:** Shows particular strength in its late-stage pipeline of **ADCs** (*Enhertu*, *Datroway*, AZD0901) and **Bispecific Antibodies** across multiple targets and platforms (e.g., *rilvegostomig*, *volrustomig*).[19] They also have approved/late-stage assets in other novel classes like LAABs (*Kavigale*) [19] and ASOs (*Wainua*).[18] While investing in cell and gene therapy [18], their late-stage presence seems less prominent than J&J's based on current pipeline disclosures.
- **Johnson & Johnson:** Has established early leadership in **CAR-T therapy** with the Japanese approval of *Carvykti* and ongoing Phase 3 trials [36], aggressively bolstered by acquisitions and collaborations targeting next-generation CAR-T

platforms.[42] They also possess a strong and growing pipeline of **Bispecific Antibodies**, particularly in hematology (*Tecvayli*, *Talvey*).[36] Furthermore, J&J is actively advancing **Gene Therapy** candidates (especially in retina) [36] and pioneering novel **oral modalities** for immunology (*Icotrokinra*, KP-723).[36]

This suggests a dynamic where AZ may exert stronger competitive pressure via ADCs and certain bispecifics in the nearer term, while J&J pushes aggressively to lead in cell/gene therapy and potentially disrupt immunology markets with novel oral agents.

5.4 Strategic Approaches

While both companies leverage global strength and local partnerships, their highlighted strategic nuances differ:

- **AstraZeneca:** Places unique emphasis on its **RWD platform and strategy** in Japan, aiming for broader healthcare ecosystem engagement beyond drug development.[15] Their partnership model often involves large-scale co-commercialization deals with major players like Daiichi Sankyo and historically Janssen itself.[1] Their therapeutic focus appears slightly more concentrated around established core areas.
- **Johnson & Johnson:** Appears to rely more heavily on the **breadth and scale of its global pipeline** as the primary driver.[9] Their external innovation strategy seems characterized by frequent, targeted **acquisitions or licensing deals** to secure specific technologies or assets that bolster modality leadership (e.g., Momenta, CBMG, Serotiny, Kaken).[39] Their therapeutic coverage seems slightly broader, with significant depth across Oncology, Immunology, and Neuroscience.

The competition between AZ and J&J in Japan can be viewed as a clash between AZ's strategy of deep penetration in core areas, augmented by a unique RWD-driven ecosystem approach, and J&J's strategy leveraging broad pipeline scale across a wider therapeutic footprint, fueled by aggressive modality-focused business development.

5.5 Comparative Overview Table

The following table summarizes key comparative points:

Feature	AstraZeneca	Johnson & Johnson (Janssen)
Stated Approval Goal (Japan)	40+ approvals (2025-2030) [15]	~50 approvals (by 2029) [9]
Key Therapeutic Areas (Japan Focus)	1. Oncology, 2. CVRM, 3. R&I, (4. Rare Disease) [15]	1. Oncology, 2. Immunology, 3. Neuroscience [9]
Key New Modalities (Late-Stage Emphasis)	ADCs, Bispecifics, LAABs, ASOs [19]	CAR-T, Bispecifics, Gene Therapy (Retina), Novel Oral Peptides/Inhibitors [36]
Unique Strategic Lever Highlighted (Japan)	RWD Platform & Ecosystem Engagement [15]	Global Pipeline Scale & Breadth, Targeted Tech/Asset Acquisition [9]
Notable Recent Japan Partnership Example	Daiichi Sankyo (*Enhertu*) / BridgeBio (*acoramidis* Japan rights) [26]	Kaken Pharma (STAT6 Inhibitor) / Legend Biotech (*Carvykti*) [38]

6. Market Impact and Future Outlook

The concurrent pursuit of highly ambitious, innovation-led strategies by AstraZeneca and Johnson & Johnson is set to significantly reshape the Japanese pharmaceutical landscape in the coming years.

6.1 Implications for Competition

The sheer volume of planned approvals (a combined target approaching 100 by 2030) will inevitably intensify competition, particularly in the crowded fields of Oncology and Immunology. This influx of novel therapies, including many

first-in-class or best-in-class agents utilizing new modalities, will likely accelerate the adoption of cutting-edge treatments but also exert considerable pressure on market share for existing therapies and competitors.[7] Success will increasingly depend not just on demonstrating clinical efficacy and safety, but also on sophisticated market access strategies, achieving rapid regulatory review and launch (thus mitigating the "drug lag" [9]), and potentially leveraging novel value demonstration tools, such as AZ's RWD initiative.[15] Smaller pharmaceutical companies, including domestic Japanese firms, may find it increasingly challenging to compete directly in these core therapeutic areas dominated by AZ and J&J's pipelines, potentially driving further consolidation or necessitating highly focused niche strategies.[6]

6.2 Impact on Japanese Healthcare

From a healthcare system perspective, the activities of AZ and J&J offer the potential for substantial benefits. Patients stand to gain accelerated access to innovative medicines addressing significant unmet needs, particularly in complex diseases prevalent in the aging population, such as cancer, autoimmune disorders, and potentially neurological conditions.[5]

However, the widespread introduction of complex new modalities like cell therapies, gene therapies, and sophisticated biologics will demand adaptation from the healthcare infrastructure. This includes ensuring the availability of specialized treatment centers, developing robust logistical pathways for personalized or sensitive therapies, and establishing appropriate reimbursement frameworks. The significant investments and market-shaping activities of AZ and J&J may, in fact, serve as catalysts, driving the necessary evolution of the Japanese healthcare system to accommodate these advanced treatments. The parallel push by these two global leaders could significantly accelerate the modernization of specific aspects of healthcare delivery and assessment in Japan.

Furthermore, the success or failure of AstraZeneca's prominent RWD strategy [15] could have broader implications. If AZ successfully utilizes its platform and certifications to generate compelling real-world evidence that influences regulatory decisions, reimbursement, or clinical practice guidelines, it could set a powerful precedent. This might encourage wider adoption of RWD by other companies, regulators (PMDA/MHLW), and healthcare providers in Japan, shifting the paradigm for evidence generation and value assessment beyond traditional clinical trials.

6.3 The Evolving Landscape

Looking ahead, several key trends will continue to shape the Japanese pharmaceutical market:

- **Innovation as the Engine:** The relentless pursuit of innovation, particularly through the development and adoption of new therapeutic modalities, will remain the primary driver of growth and competitive differentiation.[3]
- **Regulatory and Pricing Environment:** Government policies concerning drug pricing and reimbursement will continue to be critical variables influencing market attractiveness, investment decisions, and the viability of commercial strategies.[4] Balancing the need to reward innovation with cost-containment pressures will remain a central challenge.
- **Digital Transformation:** The integration of digital technologies, including AI and ML in R&D, advanced data analytics (like RWD), and digital health solutions, will become increasingly integral to pharmaceutical operations and strategies.[3]

7. Conclusion and Strategic Recommendations

The Japanese pharmaceutical market is entering a period of dynamic change, spearheaded by the ambitious, innovation-focused strategies of AstraZeneca and Johnson & Johnson. Both companies are poised to significantly impact patient care and market dynamics through their commitment to launching a high volume of new therapies, driven heavily by advancements in new modalities, between 2025 and 2030. Their parallel efforts underscore Japan's critical role in global pharmaceutical strategy, driven by its market size and the healthcare needs of its aging population.

Comparative Assessment

- **AstraZeneca:** Strengths lie in its focused pipeline within core therapeutic areas (Oncology, CVRM, R&I, Rare Diseases), particularly its late-stage dominance in ADCs and certain bispecifics, and its unique, potentially differentiating RWD strategy tailored for Japan. A relative weakness might be a less visibly advanced late-stage pipeline in cell/gene therapy compared to J&J. Opportunities reside in leveraging RWD for market access and demonstrating value. Threats include intense competition from J&J's scale and persistent pricing pressures.

- **Johnson & Johnson:** Strengths include the sheer scale and breadth of its global pipeline across multiple TAs (including Neuroscience), established leadership in CAR-T, aggressive investment in next-generation cell/gene therapies, and pioneering novel oral immunology agents. A potential weakness could be managing execution across such a broad front. Opportunities lie in leading the adoption curve for complex modalities like cell/gene therapy. Threats include pricing pressures and the focused competitive approach of AZ in overlapping areas.

Strategic Recommendations

- **For AstraZeneca:** Continue to aggressively advance the ADC and bispecific pipelines where it holds a potential near-term advantage. Fully leverage the RWD platform not just for research but as a strategic tool for market access negotiations and demonstrating long-term value to the Japanese healthcare system. Prioritize ruthlessly within the 40+ approval target to ensure successful launch execution for the most impactful therapies.
- **For Johnson & Johnson:** Focus on seamless execution across its broad pipeline to meet the ambitious ~50 approval target. Capitalize on the early lead in CAR-T (*Carvykti*) and rapidly advance next-generation cell/gene therapy assets to solidify long-term leadership in these transformative modalities. Ensure clear differentiation and value propositions for its multiple assets within crowded therapeutic areas like multiple myeloma and immunology. Continue to strategically leverage targeted acquisitions and licensing to fill gaps and access cutting-edge technology.
- **For Competitors:** Identify niche areas or specific patient populations less prioritized by AZ and J&J. Seek strategic partnerships to bolster pipelines or commercial reach. Focus intensely on differentiation – whether through unique mechanisms of action, improved convenience, or superior patient support programs. Consider leveraging Japan-specific R&D strengths.
- **For Policymakers (PMDA/MHLW):** Continue efforts to streamline regulatory pathways for innovative medicines, particularly new modalities, while balancing safety and efficacy standards (addressing drug lag). Develop clear and predictable frameworks for the assessment and reimbursement of complex therapies like cell and gene therapies, potentially incorporating real-world evidence alongside clinical trial data. Foster an environment that encourages continued R&D investment while ensuring sustainable healthcare spending.
- **For Investors:** Closely monitor the execution of both companies against their

stated approval targets and timelines in Japan. Track key clinical trial readouts and regulatory milestones, particularly for novel modality assets. Assess the impact of pricing policies and market access negotiations on commercial potential. Evaluate the success of AZ's RWD strategy and J&J's cell/gene therapy advancements as potential indicators of long-term competitive positioning.

In conclusion, the battle for leadership in the Japanese pharmaceutical market between AstraZeneca and Johnson & Johnson will be defined by innovation, strategic execution, and the successful deployment of next-generation therapies. While challenging, their competing ambitions promise to accelerate medical progress for patients in Japan.

Works cited

1. AstraZeneca signs agreement in Japan with Daiichi Sankyo to co-promote denosumab for cancer, accessed April 15, 2025, https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-signs-agreement-in-japan-with-daiichi-sankyo-to-co-promote-24052011.html
2. AstraZeneca outlines strategy to return to growth and achieve scientific leadership, accessed April 15, 2025, https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-growth-scientific-leadership-strategy-21032013.html
3. Japan Pharmaceutical Market Size & Industry 2025-33 - IMARC Group, accessed April 15, 2025, https://www.imarcgroup.com/japan-pharmaceutical-market
4. Japan Pharmaceutical Market - Size, Companies & Growth - Mordor Intelligence, accessed April 15, 2025, https://www.mordorintelligence.com/industry-reports/japan-pharmaceutical-market
5. Drug Lag and Loss: Japan's Prescription for Progress, accessed April 15, 2025, https://bccjapan.com/news/drug-lag-and-loss-japans-prescription-progress
6. Medium-term Outlook for Japanese Industry - Mizuho Financial Group, accessed April 15, 2025, https://www.mizuhogroup.com/binaries/content/assets/pdf/mizuho-bank/insights/industry/1073_en.pdf
7. AstraZeneca to Justify its Current Price in the Long Term - Focus Finance, accessed April 15, 2025, https://www.focusfinance.org/post/astrazeneca-to-justify-its-current-price-in-the-long-term

8. Global Use of Medicines 2024 - IQVIA, accessed April 15, 2025, https://www.iqvia.com/-/media/iqvia/pdfs/china/viewpoints/iqvia-institute-general-use-of-medicines-2024-for-print.pdf
9. 米J＆Jが新薬で50件承認へ 27年の2桁成長目指す | 財界オンライン, accessed April 15, 2025, https://www.zaikai.jp/articles/detail/4491
10. Breakthroughs or bottlenecks? Pharma industry outlook, trends and strategies for 2025 - ZS, accessed April 15, 2025, https://www.zs.com/insights/pharmaceutical-trends-2025-outlook-ai-supplychain-and-beyond
11. Aiming to become a country where innovation thrives, accessed April 15, 2025, https://www.jpma.or.jp/english/about/about/eki4g60000006aif-att/JPMA_guide2024_EN.pdf
12. AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment, accessed April 15, 2025, https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-janssen-japan-prostate-cancer-treatment-11102013.html
13. Our areas of partnering interest - AstraZeneca, accessed April 15, 2025, https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html
14. Reaching the 2 billion: The Japanese pharmaceutical industry and access to medicine, accessed April 15, 2025, https://accesstomedicinefoundation.org/medialibrary/resources/5bc5ee01d65c5_reaching_the_2_billion-_the_japanese_pharmaceutical_industry_and_access_to_medicine.pdf
15. AZ・堀井社長 30年までに40件以上の承認取得を目指す RWD活用で ..., accessed April 15, 2025, https://www.mixonline.jp/tabid55.html?artid=78192
16. 30年までに40件の承認取得目指す AZ・堀井社長「新モダリティにも ..., accessed April 15, 2025, https://nk.jiho.jp/article/198265
17. AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030, accessed April 15, 2025, https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-deliver-80bn-revenue-by-2030.html
18. Ambition 2030 and beyond - AstraZeneca, accessed April 15, 2025, https://www.astrazeneca.com/content/dam/az/Investor_Relations/events/ID/AstraZeneca-Ambition-2030-presentation.pdf
19. Pipeline - AstraZeneca, accessed April 15, 2025, https://www.astrazeneca.com/our-therapy-areas/pipeline.html
20. Turning science into medicine - AstraZeneca R&D, accessed April 15, 2025, https://www.astrazeneca.com/content/dam/az/r-and-d/pdf/turning-science-into-medicine.pdf
21. AstraZeneca in Japan, accessed April 15, 2025, https://careers.astrazeneca.com/japan

22. AstraZeneca 6 February 2025 Full Year and Q4 2024 results Strong momentum in FY 2024 with Total Revenue and Core EPS up, accessed April 15, 2025, https://www.astrazeneca.com/content/dam/az/PDF/2024/fy/Full-year-and-Q4-2024-results-announcement.pdf
23. IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers - AstraZeneca US, accessed April 15, 2025, https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-based-regimen-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-event-free-survival-in-resectable-early-stage-gastric-and-gastroesophageal-junction-cancers.html
24. IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial - AstraZeneca US, accessed April 15, 2025, https://www.astrazeneca-us.com/media/press-releases/2023/imfinzi-durvalumab-plus-chemotherapy-significantly-improved-pathologic-complete-response-in-gastric-and-gastroesophageal-junction-cancers-in-matterhorn-phase-iii-trial-06022023.html
25. 報道関係者の皆さま - アストラゼネカ, accessed April 15, 2025, https://www.astrazeneca.co.jp/media.html
26. Press Release - ENHERTU® Approved in Japan as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer - Daiichi Sankyo, accessed April 15, 2025, https://www.daiichisankyo.com/files/news/pressrelease/pdf/202303/20230327_E.pdf
27. AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio, accessed April 15, 2025, https://www.astrazeneca.com/media-centre/press-releases/2024/az-unveils-latest-research-across-key-respiratory-and-immune-mediated-diseases-at-ats-2024-showcasing-strength-of-its-broad-pipeline-and-portfolio.html
28. Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps - AstraZeneca US, accessed April 15, 2025, https://www.astrazeneca-us.com/media/press-releases/2025/Positive-results-from-the-TEZSPIRE-Phase-III-WAYPOINT-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps.html
29. Next generation therapeutics - AstraZeneca, accessed April 15, 2025, https://www.astrazeneca.com/r-d/next-generation-therapeutics.html
30. AstraZeneca celebrates latest successful trial of acoramidis in Japan - Morningstar, accessed April 15, 2025,

https://www.morningstar.co.uk/uk/news/AN_1706863137893331100/astrazeneca-celebrates-latest-successful-trial-of-acoramidis-in-japan.aspx
31. アストラゼネカの長期間作用型モノクローナル抗体「カビゲイル」、免疫不全患者さんに対するSARS-CoV-2による感染症の発症抑制を適応として承認取得, accessed April 15, 2025, https://www.astrazeneca.co.jp/media/press-releases1/2024/2024122701.html
32. 2024年に日米欧で承認された主な新薬まとめ（3）―循環器・代謝・腎／消化器／皮膚／感染症／ワクチン／その他 | AnswersNews - Answers（アンサーズ）, accessed April 15, 2025, https://answers.ten-navi.com/pharmanews/29587/
33. Johnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical Business Review Meeting - PR Newswire, accessed April 15, 2025, https://www.prnewswire.com/news-releases/johnson--johnson-showcases-strong-pipeline-of-transformational-medicines-at-its-pharmaceutical-business-review-meeting-300458974.html
34. Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review, accessed April 15, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-outlines-strategy-to-deliver-above-market-growth-at-2019-pharmaceutical-business-review
35. Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches, accessed April 15, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-strategies-for-growth-through-differentiated-medicines-transformational-pipeline-and-global-product-launches
36. Development pipeline - investor.jnj.com, accessed April 15, 2025, https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx
37. Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO, accessed April 15, 2025, https://www.janssen.com/janssen-aims-define-new-standards-care-treatment-solid-tumor-cancers-transformative-data-planned
38. CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma - Legend Biotech, accessed April 15, 2025, https://legendbiotech.com/legend-news/carvykti-receives-approval-from-japans-ministry-of-health-labour-and-welfare-mhlw/
39. ジョンソン・エンド・ジョンソン、Momenta Pharmaceuticals Inc.を買収し、自己免疫疾患の新規治療におけるヤンセンのパイプラインを拡大, accessed April 15, 2025, https://innovativemedicine.jnj.com/japan/press-release/20200820

40. J&J）2024年第4四半期および通年の財務とパイプライン概要 | PharmaUpdates - note, accessed April 15, 2025, https://note.com/an_an908/n/ne284cdbc7f9f
41. Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, accessed April 15, 2025, https://www.janssen.com/ja/node/71101
42. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies, accessed April 15, 2025, https://www.jnj.com/media-center/press-releases/janssen-enters-worldwide-collaboration-and-license-agreement-with-cellular-biomedicine-group-to-develop-next-generation-car-t-therapies
43. Johnson & Johnson highlights its preeminent leadership in hematology through differentiated blood cancer portfolio and pipeline with new clinical and real-world data at ASH | Janssen, accessed April 15, 2025, https://www.janssen.com/johnson-johnson-highlights-its-preeminent-leadership-hematology-through-differentiated-blood-cancer
44. Serotiny's journey to transform cell & gene therapy: From startup to J&J acquisition, accessed April 15, 2025, https://jnjinnovation.com/news/blog-post/serotinys-journey-to-transform-cell--gene-therapy-from-startup-to-jj-acquisition
45. Janssen Highlights Innovative Oncology Portfolio and Pipeline of Oral, Biologic and Cell Therapies Through ASCO20 Virtual Scientific Program - BioSpace, accessed April 15, 2025, https://www.biospace.com/janssen-highlights-innovative-oncology-portfolio-and-pipeline-of-oral-biologic-and-cell-therapies-through-asco20-virtual-scientific-program
46. innovative-medicine-presentation.pdf, accessed April 15, 2025, https://s203.q4cdn.com/972069832/files/doc_downloads/2023/12/innovative-medicine-presentation.pdf
47. Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis, accessed April 15, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis
48. Johnson & Johnson Innovative Medicine, accessed April 15, 2025, https://www.janssen.com/japan/press-release/20241227-3
49. A Spotlight on Our Collaborations in Asia Pacific | Johnson & Johnson Innovation, accessed April 15, 2025, https://jnjinnovation.com/pages/a-spotlight-on-our-collaborations-in-asia-pacific-2022
50. グローバル展開 医薬品事業 会社情報 日本新薬, accessed April 15, 2025, https://www.nippon-shinyaku.co.jp/company_profile/medical/oversea.php
51. Product Strategy & Development Pipeline, accessed April 15, 2025,

https://www.mt-pharma.co.jp/e/company/financial-information/pdf/e_presen101101_M.pdf
52. 高齢化社会の課題を産官学スタートアップの協力で解決する ージョンソン・エンド・ジョンソン日本法人グループ クイックファイアーチャレンジ開催へー - LINK-J, accessed April 15, 2025, https://www.link-j.org/event/post-8790.html
53. 2025 life sciences outlook | Deloitte Insights, accessed April 15, 2025, https://www2.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-life-sciences-executive-outlook.html